The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Abstract
The sex hormone estrogen is important for many physiologic processes. Prolonged stimulation of breast ductal epithelium by estrogen, however, can contribute to the development and progression of breast cancer, and treatments designed to block estrogen’s effects are important options in the clinic. Tamoxifen and other similar drugs are effective in breast cancer prevention and treatment by inhibiting the proliferative effects of estrogen that are mediated through the estrogen receptor (ER). However, these drugs also have many estrogenic effects depending on the tissue and gene, and they are more appropriately called selective estrogen receptor modulators (SERMs). SERMs bind ER, alter receptor conformation, and facilitate binding of coregulatory proteins that activate or repress transcriptional activation of estrogen target genes. Theoretically, SERMs could be synthesized that would exhibit nearly complete agonist activity on the one hand or pure antiestrogenic activity on the other. Depending on their functional activities, SERMs could then be developed for a variety of clinical uses, including prevention and treatment of osteoporosis, treatment and prevention of estrogen-regulated malignancies, and even for hormone replacement therapy. Tamoxifen is effective in patients with ER-positive metastatic breast cancer and in the adjuvant setting. The promising role for tamoxifen in ductal carcinoma-in-situ or for breast cancer prevention is evolving, and its use can be considered in certain patient groups. Other SERMs are in development, with the goal of reducing toxicity and/or improving efficacy, and future agents have the potential of providing a new paradigm for maintaining the health of women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β
Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., & Gustafsson, J.-Å. (1998) · Endocrinology · doi:10.1210/endo.139.10.6216 · Cited by 4,203
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
ERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Cited by
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Musa, M., Cooperwood, J., & Khan, M. O. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242877 · Cited by 538
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Self-citationOsborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Self-citationMeeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Love, R. R., Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.7.1955 · Cited by 414
Soy for Breast Cancer Survivors: A Critical Review of the Literature
Messina, M. J., & Loprinzi, C. L. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.11.3095s · Cited by 359
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Osborne, C. K., & Schiff, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.036 · Cited by 351
Self-citationNon-genomic actions of estrogens and their interaction with genomic actions in the brain
Vasudevan, N., & Pfaff, D. W. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.08.003 · Cited by 343
Aromatase inhibitors for breast cancer: lessons from the laboratory
Johnston, S. R. D., & Dowsett, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1211 · Cited by 326
Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen, L., Jalink, K., Floore, A., Velds, A., van `t Veer, L., & Neefjes, J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.016 · Cited by 260
Jain, A. K., Swarnakar, N. K., Godugu, C., Singh, R. P., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.037 · Cited by 232
Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles
Vasudevan, N., & Pfaff, D. W. (2007) · Endocrine Reviews · doi:10.1210/er.2005-0021 · Cited by 231
Influence of Sex Hormones on Cancer Progression
Folkerd, E. J., & Dowsett, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4290 · Cited by 229
Hirrlinger, P. G., Scheller, A., Braun, C., Hirrlinger, J., & Kirchhoff, F. (2006) · Glia · doi:10.1002/glia.20342 · Cited by 200
Metadata
- Authors
- Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-09-17
- Volume
- 18
- Issue
- 17
- Pages
- 3172-3186
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955010715
- Cited by
- 367
- References
- 113
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.